RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

Panagiotis Kottaridis, Rosemary E. Gale, Marion E. Frew et al. · Blood · 2001 · 1.5K citations · Full text

Life Sciences, Genetics, Hematology +16

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

Rosemary E. Gale, Claire Green, Christopher Allen et al. · Blood · 2007 · 744 citations

Medicine, Genetics, Molecular Genetics +15

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

Soheil Meshinchi, William G. Woods, Derek L. Stirewalt et al. · Blood · 2001 · 517 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

Hitoshi Kiyoi, Masayuki Towatari, Shohei Yokota et al. · Leukemia · 1998 · 451 citations

Life Sciences, Genetics, Molecular Genetics +13

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

Steven Knapper, Alan K. Burnett, Tim Littlewood et al. · Blood · 2006 · 413 citations · Full text

Medicine, Oncology, Pharmacology +10